Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
PMID: 20008905
2010
The Journal of antimicrobial chemotherapy
Result: However, when analysed by CG, low-abundance viral species containing resistance mutations were detected in three of these four subjects at VF (L210W for Subject 8, Y188L for Subject 12 and M184I for Subject 13).
Result: The L210W and M184I mutations were treatment emergent for Subjects 8 and 13, respectively, while the NNRTI mutation Y188L that was observed by CG at VF for Subject 12 had also been detected at baseline by CG (but not by PG).
Table: M184I
Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals.
PMID: 20038617
2010
Antimicrobial agents and chemotherapy
Abstract: Amdoxovir (AMDX) inhibits HIV-1 containing the M184V/I mutation and is rapidly absorbed and deaminated to its active metabolite, beta-D-dioxolane guanosine (DXG).
N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
Conclusion: This finding is consistent with recent studies that show a strong association between N348I with TAMs, M184V/I and Y181C or that N348I is frequently observed in AZT- and/or ddI-containing therapies.
Introduction: N348I appears early in therapy and was found to be highly associated with TAMs, M184V/I and the NNRTI resistance mutations K103N, Y181C/I, and G190A/S.
HIV-1 proviral resistance mutations: usefulness in clinical practice.
Abstract: The nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations found were as follows: 85% of the children had M184V/I, 23% had at least four thymidine analogue mutations, 12% had the Q151M complex, 5% had K65R, and 1% had the 69 insertion.
Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals.
Introduction: DXG has shown good activity in vitro against HIV-1 strains resistant to lamivudine or emtricitabine (M184V/I) and strains containing zidovudine/stavudine-resistant thymidine analogue mutations (TAMs), including the 69SS double insert.
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.
Abstract: M184V/I, K103N and V106A/M were the most common mutations.
Result: Among the 35 viremic patients failing a second-line regimen, 29% (n=10), 54% (n=19) and 6% (n=2) patients had mutations associated with NRTI resistance (mainly M184V/I, n=9), NNRTI resistance (mainly K103N, n=15), and major PI mutations respectively.
Result: Of the 94 viremic patients on the first-line regimen, 64% (n=60), 81% (n=76), and 2% (n=2) had evidence of NRTI, NNRTI, and PI resistance respectively; M184V/I and K103N<
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
PMID: 20462946
2010
The Journal of antimicrobial chemotherapy
Method: We also examined the extent to which the 52 NNRTI-selected mutations covaried with mutations at 12 major nucleoside reverse transcriptase inhibitor (NRTI) resistance positions, including M41L, K65R, D67N, T69S_SS, K70E, K70R, L74V, L74I, V75M/T, Y115F, Q151M, M184V/I, L210W, T215F and T215Y.
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Discussion: M184V/I single-mutants comprised 48% of all sequences, whereas only two sequences (1%) were K65R
Discussion: A negative drug-drug interaction between TNV and other NRTIs has also been proposed as an escape mechanism of M184V/I single-mutants from TNV suppression.
Discussion: By week 12, double-mutants containing K65R and M184V/I were predominant in all five subjects.
Discussion: Escape of M184I/V single-mutants remains unexplained because these viruses were fully susceptible or hypersusceptible to TNV.
Discussion: Linkage analysis showed K65R and M184V/I single-mutants were more prevalent at week 4 than at week 12.
Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study.
Result: Considering specific TDRs that could impact virologic response to the N(t)RTI backbone, TDF/FTC, used in the study, 9 (6.4%) of the subjects had M184V/I identified by UDS at baseline.
Result: Of the 141 subjects with a UDS result, 35 (24.8%) had a nucleoside(tide) reverse transcriptase inhibitor N(t)RTI(s) TDR; 26 of these had a thymidine analog mutation (TAM), 9 had a M184V/I, and 2 had a variant with a K65R.
Result: Specific TDR patterns and levels for subjects with a M184V/I and K65R are shown in Table 4.
HIV mutation literature information.
PMID: 
2010
The Journal of antimicrobial chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT